Ionis Pharmaceuticals

Recent news

• Rating change
  H.C. Wainwright Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $100
  Market Newswire · 2026/9/24
• Rating change
  Goldman Sachs Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Cuts Target Price to $56
  Market Newswire · 2026/9/14
• A Quick Look at Today's Ratings for Ionis Pharmaceuticals(IONS.US), With a Forecast Between $70 to $100
  Market Newswire · 2026/9/23
• CCORF Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $85
  Market Newswire · 2026/9/25
• Rating change
  CCORF Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $95
  Market Newswire · 2026/9/4
• Rating change
  BMO Capital Downgrades Ionis Pharmaceuticals(IONS.US) to Hold Rating, Cuts Target Price to $61
  Market Newswire · 2026/9/4
• Rating change
  A Quick Look at Today's Ratings for Ionis Pharmaceuticals(IONS.US), With a Forecast Between $84 to $104
  Market Newswire · 2026/9/9
• Oppenheimer Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Cuts Target Price to $85
  Market Newswire · 2026/9/25
• Rating change
  A Quick Look at Today's Ratings for Ionis Pharmaceuticals(IONS.US), With a Forecast Between $61 to $115
  Market Newswire · 2026/9/5
• Rating change
  Barclays Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $90
  Market Newswire · 2026/9/1
• Company notice
  Liberta: Announcement that Family Service Eiko Co., Ltd. will hold a press conference for the first time in Tokyo to remove heavy metal ions, PFOS, and PFOA removal water server “swee,” which was jointly developed by Family Service Eiko Co., Ltd. with Shinshu University
  JPX · 2025/4/11
• Rating change
  Guggenheim Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Cuts Target Price to $80
  Market Newswire · 2026/9/15
• BMO Capital Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Cuts Target Price to $54
  Market Newswire · 2026/9/24
• A Quick Look at Today's Ratings for Ionis Pharmaceuticals(IONS.US), With a Forecast Between $84 to $100
  Market Newswire · 2026/9/24
• Rating change
  Analysts Offer Insights on Healthcare Companies: Maze Therapeutics, Inc. (MAZE) and Ionis Pharmaceuticals (IONS)
  TipRanks · 2026/9/23
• Rating change
  J.P. Morgan Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Cuts Target Price to $70
  Market Newswire · 2026/9/22
• Rating change
  Morgan Stanley Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $104
  Market Newswire · 2026/9/10
• Company notice
  Cacco: Ion's online market, "Green Beans", has adopted "O-PLUX" as a measure against credit card fraud.
  JPX · 2024/6/6
• Rating change
  Barclays Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $85
  Market Newswire · 2026/9/18
• Rating change
  H.C. Wainwright Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $115
  Market Newswire · 2026/9/4

Headlines are aggregated automatically and are not independently verified or edited by our team.